Addiction Medicine 2027 Longitudinal Assessment References
Due to copyright restrictions, the Addiction Medicine Conjoint Committee cannot provide most reference materials used for longitudinal assessment. However, a list of references used for the 2027 longitudinal assessment can be found below.
- National Institute on Drug Abuse (Updated Jan 2024); Psychedelic and dissociative drugs as medicines
https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs-medicines - U.S. Food & Drug Administration (Updated Oct 2023); FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders
https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine - Journal of Addiction Medicine (Sep-Oct 2023); Vol. 17, Issue 5; Evidence on buprenorphine dose limits: a review; pg. 509-516
- Experimental and Clinical Psychopharmacology (Aug 2020); Vol. 28, Issue 4; Translational dynamics of alcohol tolerance of preclinical models and human laboratory studies; pg. 417-425
- Infectious Disease Clinics of North America (Sep 2020); Vol. 34, Issue 3; Infective endocarditis in persons who use drugs: epidemiology, current management, and emerging treatments; pg. 479-493
- Pediatrics (Sep 2024); Vol. 154, Issue 3; Substance use screening among youth in foster care
- https://publications.aap.org/pediatrics/article-abstract/154/3/e2023065057/198911/Substance-Use-Screening-Among-Youth-in-Foster-Care?redirectedFrom=fulltext
- Federal Register (Jul 2020); Vol. 85, No. 136; Confidentiality of substance use disorder patient records
- Journal of the Endocrine Society (Nov 2025); Vol. 9, Issue 11; GLP-1 therapeutics and their emerging role in alcohol and substance use disorders: an endocrinology primer
https://www.govinfo.gov/content/pkg/FR-2020-07-15/pdf/2020-14675.pdf - Substance Abuse and Rehabilitation (Aug 2023); Vol. 14; Updated perspectives on the neurobiology of substance use disorders using neuroimaging; pg. 99-111
https://pubmed.ncbi.nlm.nih.gov/37583934/ - The Management of Substance Use Disorders Work Group (Aug 2021); VA/DoD clinical practice guideline for the management of substance use disorders
https://www.healthquality.va.gov/guidelines/MH/sud/VA-DoD-SUD-CPG_Final_for-508_v3.pdf - The New England Journal of Medicine (Jan 2016); Vol. 374, Issue 4; Neurobiologic advances from the brain disease model of addiction; pg. 363-371
https://pubmed.ncbi.nlm.nih.gov/26816013/ - The Lancet Psychiatry (Aug 2016); Vol. 3, Issue 8; Neurobiology of addiction: a neurocircuitry analysis; pg. 760-773
https://pubmed.ncbi.nlm.nih.gov/27475769/ - Frontiers in Psychiatry (Dec 2021); Vol. 12; The impact of co-occurring post-traumatic stress disorder and substance use disorders on craving: a systematic review of the literature
- StatPearls (Updated Jul 2025); Prescription of controlled substances: benefits and risks
https://www.ncbi.nlm.nih.gov/books/NBK537318/#article-40661.s2 - American Heart Association (Updated Oct 2023); First responders who keep us safe need to care for themselves, too
https://www.heart.org/en/news/2023/10/27/first-responders-who-keep-us-safe-need-to-care-for-themselves-too - Substance Abuse and Mental Health Services Administration (Updated May 2018); Disaster Technical Assistance Center Supplemental Research Bulletin: First responders: behavioral health concerns, emergency response, and trauma
https://www.samhsa.gov/sites/default/files/dtac/supplementalresearchbulletin-firstresponders-may2018.pdf - Safety and Health at Work (Sep 2022); Vol. 13, Issue 4; Norms about alcohol use among US firefighters; pg. 387-393
https://pmc.ncbi.nlm.nih.gov/articles/PMC9772477/ - U.S. Department of Health and Human Services (Updated Jan 2026); Fact sheet 42 CFR Part 2 final rule https://www.samhsa.gov/about/faqs/confidentiality-regulations
https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html - Substance Abuse and Mental Health Services Administration (Updated Oct 2023); Frequently asked questions
- Substance Abuse and Mental Health Services Administration (Updated 2019); Treatment Improvement Protocol (TIP) 35: Enhancing motivation for change in substance use disorder treatment
https://library.samhsa.gov/sites/default/files/tip-35-pep19-02-01-003.pdf - The ASAM Principles of Addiction Medicine, 7th ed. (2024); Ch. 18; pg. 275
The American Journal of Psychiatry Residents’ Journal (Mar 2025); Vol. 20, Issue 3; Xylazine: a review of intoxication, overdose, and withdrawal symptoms
https://psychiatryonline.org/doi/10.1176/appi.ajp-rj.2025.200303 - StatPearls (Updated Jul 2023); Xylazine toxicity
https://www.ncbi.nlm.nih.gov/books/NBK594271/